Compare ALEMBIC with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs SUN PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC SUN PHARMA ALEMBIC/
SUN PHARMA
 
P/E (TTM) x 78.6 84.2 93.4% View Chart
P/BV x 6.8 3.6 188.8% View Chart
Dividend Yield % 0.2 0.6 25.4%  

Financials

 ALEMBIC   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
SUN PHARMA
Mar-20
ALEMBIC/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs72484 14.9%   
Low Rs34315 10.8%   
Sales per share (Unadj.) Rs4.7136.9 3.4%  
Earnings per share (Unadj.) Rs6.117.5 35.0%  
Cash flow per share (Unadj.) Rs6.226.0 24.0%  
Dividends per share (Unadj.) Rs0.204.00 5.0%  
Dividend yield (eoy) %0.41.0 37.7%  
Book value per share (Unadj.) Rs40.7188.7 21.6%  
Shares outstanding (eoy) m267.032,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.9 385.8%   
Avg P/E ratio x8.722.9 37.9%  
P/CF ratio (eoy) x8.515.4 55.2%  
Price / Book Value ratio x1.32.1 61.5%  
Dividend payout %3.322.9 14.3%   
Avg Mkt Cap Rs m14,139958,864 1.5%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m20763,624 0.3%   
Avg. sales/employee Rs ThNM18,490.6-  
Avg. wages/employee Rs ThNM3,582.6-  
Avg. net profit/employee Rs ThNM2,357.6-  
INCOME DATA
Net Sales Rs m1,255328,375 0.4%  
Other income Rs m3706,360 5.8%   
Total revenues Rs m1,625334,735 0.5%   
Gross profit Rs m11169,898 0.2%  
Depreciation Rs m3820,528 0.2%   
Interest Rs m23,027 0.1%   
Profit before tax Rs m44252,702 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m248,228 0.3%   
Profit after tax Rs m1,63041,868 3.9%  
Gross profit margin %8.921.3 41.6%  
Effective tax rate %5.415.6 34.7%   
Net profit margin %129.812.8 1,018.4%  
BALANCE SHEET DATA
Current assets Rs m1,867316,542 0.6%   
Current liabilities Rs m591157,064 0.4%   
Net working cap to sales %101.648.6 209.3%  
Current ratio x3.22.0 156.7%  
Inventory Days Days9488 107.7%  
Debtors Days Days74105 70.2%  
Net fixed assets Rs m1,791243,102 0.7%   
Share capital Rs m5342,399 22.3%   
"Free" reserves Rs m10,324450,245 2.3%   
Net worth Rs m10,858452,645 2.4%   
Long term debt Rs m4120,289 0.2%   
Total assets Rs m11,591682,525 1.7%  
Interest coverage x260.918.4 1,417.1%   
Debt to equity ratio x00 8.5%  
Sales to assets ratio x0.10.5 22.5%   
Return on assets %14.16.6 214.0%  
Return on equity %15.09.2 162.3%  
Return on capital %15.211.2 135.2%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1974,219 0.0%   
Fx outflow Rs m26427,964 0.9%   
Net fx Rs m-24446,255 -0.5%   
CASH FLOW
From Operations Rs m23665,548 0.4%  
From Investments Rs m-224-25,888 0.9%  
From Financial Activity Rs m-27-57,151 0.0%  
Net Cashflow Rs m-15-13,857 0.1%  

Share Holding

Indian Promoters % 64.0 63.7 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.1 3.9%  
FIIs % 9.7 23.0 42.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 8.3 314.5%  
Shareholders   54,701 133,026 41.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  WOCKHARDT  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Up by 53 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 191 points, up 0.4% at 48,868 levels.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 6, 2021 02:27 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS